The content on this site is intended for healthcare professionals only
Prof Mejean speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about treating metastatic renal cell carcinoma (mRCC) with sunitinib alone or sunitinib and surgery.
He outlines the stratification for patients recruited to the trail, in which the benefit of sunitinib with or without surgery for medium-risk patients was unknown, and the observed impact on disease survival.
For more on these results, watch Dr Mejean present the data in a press conference here, and read our news coverage here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Adjuvant radiotherapy has no benefit following radical prostatectomy
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
OncoAlert Round Up for September 15-21, 2023
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 11th - 17th, 2023
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
IORT at Fortis Hospital Bangalore in India
Genomic profiling of penile squamous cell carcinoma reveals major biomarkers for efficacy of immunotherapy
Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations
